Melika Davis
About Melika Davis
Melika Davis is the Senior Vice President of Global Clinical Operations at BeiGene, with over 30 years of experience in clinical research and drug development.
Company
Melika Davis currently holds the position of SVP, Global Clinical Operations at BeiGene. She joined BeiGene in August 2019, where she leads the Global Clinical Operations organization. BeiGene is a biotechnology company focused on developing innovative molecularly targeted and immuno-oncology drug candidates for the treatment of cancer.
Title
Melika Davis serves as the Senior Vice President (SVP) of Global Clinical Operations at BeiGene. In this role, she focuses on transforming clinical trials to accelerate the process of saving lives globally. She brings over 30 years of experience in clinical research and drug development to her current position.
Education and Expertise
Melika Davis received her Bachelor of Science (BS) in Biology from Texas Woman's University in Dallas and later earned her Master of Science (MS) in Molecular Biology from the same institution. Additionally, she holds a Licentiate degree in Cell Biology and Physiology, Animal Physiology from Université Côte d'Azur in Nice, France. Her extensive academic background laid the foundation for her expertise in clinical research and drug development.
Background
Before joining BeiGene, Melika Davis spent a significant portion of her career at Novartis and Schering-Plough Research Institute. At Novartis, she held several key positions, including SVP, Global Head of Drug Development Quality, and VP, Head of Global Medical & Monitoring Operations. She also worked at Schering-Plough Research Institute in roles of increasing responsibility for 13 years, starting as an Associate Scientist in Tumor Biology and later becoming Associate Director of Clinical Research.
Achievements
Melika Davis is recognized for her role in building innovative and effective organizations in drug development. At Novartis, she led the clinical monitoring operations group for 15 years, focusing on quality assurance within clinical trials. Her leadership and expertise have been instrumental in advancing drug development processes to enhance global health outcomes.